Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lithium cation
Drug ID BADD_D01304
Description Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Indications and Usage Lithium, in its salt forms, is used as a mood stabilizer and for the treatment of depression and mania. It is most frequently prescribed in the treatment of bipolar disorder.
Marketing Status experimental
ATC Code N05AN01
DrugBank ID DB01356
KEGG ID D08133
MeSH ID D008094
PubChem ID 28486
TTD Drug ID D5MF8Y
NDC Product Code Not Available
UNII 8H8Z5UER66
Synonyms Lithium | Lithium-7 | Lithium 7
Chemical Information
Molecular Formula Li+
CAS Registry Number 17341-24-1
SMILES [Li+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Osmotic demyelination syndrome17.16.02.0040.000192%-
Toxicity to various agents12.03.01.046---
Posterior reversible encephalopathy syndrome17.13.02.0070.000384%
Resting tremor17.01.06.0080.000288%-
Action tremor17.01.06.0070.000192%-
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.000672%-
Sinus node dysfunction02.03.03.0170.000384%
Multiple organ dysfunction syndrome08.01.03.0570.000480%
Hyperadrenalism05.01.01.005; 14.11.01.028; 24.08.04.0030.000192%-
Impulsive behaviour19.18.01.0010.000192%-
Myocardial fibrosis02.04.02.0160.000192%-
Overweight14.03.02.0210.000653%-
Persecutory delusion19.10.01.0070.000192%-
Cardiomyopathy acute02.04.01.0080.000288%-
Kidney enlargement20.01.06.0030.000192%-
Live birth18.08.02.0070.000480%-
Renal oncocytoma16.27.01.008; 20.01.04.0190.001056%-
Sopor17.02.04.021; 19.02.04.0020.000384%-
Multiple system atrophy17.02.10.023; 24.06.03.0130.000192%-
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.000288%-
Clear cell renal cell carcinoma16.08.02.004; 20.01.04.0080.001536%-
End stage renal disease20.01.03.0190.001824%-
Benign renal neoplasm16.27.01.010; 20.01.04.0200.000192%-
Dilated cardiomyopathy02.04.01.0170.000192%-
Hyperglycaemic hyperosmolar nonketotic syndrome05.07.04.009; 14.07.04.009; 17.02.04.0220.000288%-
Idiopathic intracranial hypertension17.07.02.0110.000288%-
Infant irritability17.02.05.072; 18.04.04.0180.000192%-
Neonatal respiratory distress18.04.10.004; 22.11.02.0150.000768%-
Neonatal seizure17.12.03.038; 18.04.04.0190.000192%-
Oncocytoma16.02.02.0160.000192%-
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages